Ultragenyx Pharmaceutical Inc.

RARE Nasdaq SEC CIK 1515673
Follow Ultragenyx Pharmaceutical Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $173M +8.1% vs same quarter last year
Net income −$118M +34.4% vs same quarter last year
EPS, diluted −$1.16 +35.9% vs same quarter last year
Operating cash flow −$43M +52.7% vs same quarter last year
Revenue by quarter
$164.6M
$139M
$167M
$160M
$207M
$136M
$214M
$173M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$1B−$500M$0$500M$1BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$673M−$575M
FY24$560M−$569M
FY23$434M−$607M
FY22$363.3M−$707.4M
FY21$351.4M−$454M
FY20$271M−$186.6M
FY19$103.7M−$402.7M
FY18$51.5M−$197.6M
FY17$2.6M−$302.1M
FY16$133K−$245.9M
FY15-−$145.6M
FY14-−$59.8M
FY13-−$35.1M
FY12-−$16.3M
FY11--
MarginsShare of revenue
  • Operating margin
  • Net margin
−200000%−150000%−100000%−50000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−79.5%−85.4%
FY24−95.7%−101.6%
FY23−131.1%−139.9%
FY22−178.6%−194.7%
FY21−108.6%−129.2%
FY20−121.8%−68.8%
FY19−409%−388.3%
FY18−721.2%−383.7%
FY17−12593.5%−11567.3%
FY16−186471.4%−184867.7%
FY15--
FY14--
FY13--
FY12--
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$600M−$400M−$200M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$472M
FY24−$421M
FY23−$519M
FY22−$496.6M
FY21−$411.8M
FY20−$176.1M
FY19−$370.2M
FY18−$294.6M
FY17−$256.6M
FY16−$171.2M
FY15−$110.9M
FY14−$46.8M
FY13−$31.6M
FY12−$13.6M
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Ultragenyx Pharmaceutical
  • Healthcare median
−200000%−150000%−100000%−50000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearUltragenyx PharmaceuticalHealthcare median
FY25−85.4%−30.6%
FY24−101.6%−47%
FY23−139.9%−58%
FY22−194.7%−80.4%
FY21−129.2%−71.8%
FY20−68.8%−62.2%
FY19−388.3%−46.2%
FY18−383.7%−49.6%
FY17−11567.3%−45.9%
FY16−184867.7%−36%
FY15-−37.8%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%
FY11-−27.9%